|
Session 95
Poster Abstracts
Predictors of ART Discontinuation, Virologic Response, and Outcomes
Tuesday, 1 - 4 pm
Poster Hall |
| 522 |
Treatment Complexity and Risk of Virological Rebound in Persons Receiving cART
Adriana Ammassari*1, A Cozzi-Lepri2, M Trotta1, P Marconi1, C Torti3, A Castagna4, A De Luca5, V Colangeli6, A Antinori1, A d'Arminio Monforte7, and ICoNA Cohort
1Natl Inst of Infectious Diseases, L Spallanzani, Rome, Italy; 2Royal Free and Univ Coll London, UK; 3Univ of Brescia, Italy; 4San Raffaele Sci Inst, Milan, Italy; 5Catholic Univ, Rome, Italy; 6Univ of Bologna, Italy; and 7Hosp Luigi Sacco, Milan, Italy |
523
 |
Prediction of Viral Rebound in HIV-infected Patients on ART Using Longitudinal Data from the Swiss HIV Cohort Study
Tracy Glass*1, S De Geest2, R Weber3, P Vernazza4, H Furrer5, E Bernasconi6, M Cavassini7, B Hirschel8, M Battegay9, H Bucher1,9, H Bucher1,9, and Swiss HIV Cohort Study
1Basel Inst for Clin Epidemiology, Switzerland; 2Inst of Nursing Sci, Basel, Switzerland; 3Univ Hosp, Zurich, Switzerland; 4Kantonsspital St Gallen, Switzerland; 5Hosp Berne, Switzerland; 6Regional Hosp Lugano, Switzerland; 7Ctr Hosp Univ Vaudois Lausanne, Switzerland; 8Univ Hosp Geneva, Switzerland; and 9Univ Hosp Basel, Switzerland |
524
|
Pill-box Organizers Are Associated with Improved Antiretroviral Adherence, and Viral Suppression and Are Cost Effective
M Petersen1, Y Wang1, M van der Laan1, D Guzman2, E Riley2, and David Bangsberg*2
1Univ of California, Berkeley Sch of Publ Hlth, US and 2Univ of California, San Francisco, US |
525
|
Survival after the First AIDS-defining Illness and Causes of Death before and after Potent ART. Results from the French Hospital Database on HIV
S Grabar1, E Lanoy2, C Allavena3, M Mary-krause2, C Rabaud4, M Bentata5, P Fischer6, A Mahamat7, C Chesnel6, and Dominique Costagliola*2
1INSERM U720, Univ Pierre and Marie Curie, Hosp Cochin, Paris, France; 2INSERM U720, Univ Pierre and Marie Curie, Paris, France; 3Ctr Hosp Univ Hotel-Dieu, Nantes, France; 4Ctr Hosp Univ de Nancy, Vandoeuvre, France; 5Hosp Avicenne, Bobigny, France; 6Hosp Henri Mondor, Creteil, France; and 7Ctr Hosp Univ de Nimes, France |
526
|
Prognosis of Patients Treated with cART from 36 Months after Initiation of Therapy, according to Current and Previous CD4 Cell Count
Jonathan Sterne and The Antiretroviral Therapy (ART) Cohort Collaboration
Univ of Bristol, UK |
| 527 |
A Comparison of Commonly Prescribed cART Regimens: Do Differences in Short-term Virologic Success Translate to Better Clinical Outcomes?
Michael Mugavero and the Antiretroviral Therapy Cohort Collaboration (ART-CC)
Univ of Alabama at Birmingham, US |
528
|
Response to Combination ART: Variation by Age
Caroline Sabin and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study
Royal Free and Univ Coll London Med Sch, UK |
| 529 |
Risk Factors and Reasons for Taking Drug Holidays from ART among Persons with HIV Infection
James Heffelfinger*, A Voetsch, G Nakamura, A McNaghten, and P Sullivan
CDC, Atlanta, GA, US |
530
|
Prevalence and Factors Associated with Discontinuation and Modification of HAART among HIV+ People in Kampala, Uganda
Ronald Kiguba*1, J Byakika-Tusiime1, F Ssali2, and E Katabira1
1Makerere Univ, Kampala, Uganda and 2Joint Clin Res Ctr, Kampala, Uganda |
531
|
Evaluation of Clinical and Laboratory Parameters to Predict Viral Response to ART in Uganda
David Meya*1, H Tibenderana1, L John1, L Spacek2, I Namugga1, S Magero1, T Quinn2, R Colebunders3, A Kambugu1, and S Reynolds2
1Infectious Disease Inst, Makerere Univ, Kampala, Uganda; 2NIAID, NIH and Johns Hopkins Univ Sch of Med, Baltimore, MD, US; and 3Inst of Tropical Med, Univ of Antwerp, Belgium |
| 532 |
Cumulative Risk of Extensive Triple-class Virologic Failure in 10,603 Patients followed as Long as 10 Years from the Start of ART
Andrew Phillips*1, A Wilson2, C Leen2, and The UK CHIC Study Group
1Royal Free and Univ Coll London Med Sch, UK and 2Western Gen Hosp, Edinburgh, Scotland, UK |
533
|
Alcohol Abuse or Dependence Is the Most Prevalent Co-morbidity among 48,384 HIV-infected VA and California Medicaid Beneficiaries
D Zingmond1, K Gordon2,3, K Gordon2,3, W Cunningham1, J Goulet2,3, J Goulet2,3, J Currier1, S Fultz2,3, S Fultz2,3, Amy C Justice*2,3, Amy C Justice*2,3, and VACS Project Team
1Univ of California, Los Angeles, US; 2Yale Univ Sch of Med, New Haven, CT, US; and 3VA Connecticut Hlthcare System, West Haven, US |
|
